The Latest Cardiac and Vascular News
Westport, CT, Aug. 05, 2020 (GLOBE NEWSWIRE) — Dr. Sofia is an Inductee in the American Chemical Society Medicinal Chemistry Hall of Fame ViralClear Pharmaceuticals is Currently in Phase 2 Trials with Merimepodib in the Fight Against COVID-19 BioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced the addition of […]
Patient cases are set to commence in August Westport, CT, Aug. 04, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the […]
Company moves forward with the qualification to bid for contacts, grants and to do business with the U.S. government Westport, CT, Aug. 03, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full […]
Westport, CT, July 20, 2020 (GLOBE NEWSWIRE) — BioSig Subsidiary Enlists Seasoned Professionals in Emerging Infectious Diseases and Regulatory Development to Its Advisory Board ViralClear Pharmaceuticals is Currently in Phase II Trials with Its Lead Asset Merimepodib in the Fight Against COVID-19 BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), […]
Westport, CT, July 16, 2020 (GLOBE NEWSWIRE) — Rights Agreement designed to assure stockholders receive fair and equal treatment in the event of any proposed takeover Provides a guard against tactics to gain control of the Company without paying stockholders a market premium for that control BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), […]
Westport, CT, July 08, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it is partnering with Albany Molecular Research Inc., (AMRI), a leading global contract research, development and manufacturing organization (CDMO), for support in undertaking research to investigate the potential of merimepodib […]
Former President and CEO of the North American division of AstraZeneca Plc to join as Independent Director Westport, CT, July 01, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range […]
Westport, CT, June 24, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 2,187,500 shares of the Company’s common stock, at a purchase price of $8.00 per share, in a registered […]
Westport, CT, June 03, 2020 (GLOBE NEWSWIRE) — U.S. Patent and Trademark Office awards Company additional patent for PURE EP™ System Five patent applications filed by ViralClear Pharmaceuticals, Inc., covering its orally administered broad-spectrum anti-viral solution for the treatment of COVID-19 BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing […]
Pharmaceutical industry leader to join as the Company prepares for the Phase II clinical trial with merimepodib, an orally administered broad-spectrum anti-viral for COVID-19 Westport, CT, May 28, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Michael R. Dougherty to the Board of Directors of its majority-owned […]
